Drug
Regn20423
Regn20423: highest development phase Phase 1, developed by Regeneron. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Regeneron
Trials
| Drug | Phase | Indication |
|---|---|---|
| REGN20423 NCT07527923 | Phase 1 | Atopic Dermatitis |
Latest
No recent events.
Follow Regn20423 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.